financetom
Business
financetom
/
Business
/
Lockmaker Allegion beats Q3 revenue estimates; lifts annual rev growth outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lockmaker Allegion beats Q3 revenue estimates; lifts annual rev growth outlook
Oct 23, 2025 3:31 AM

Overview

* Allegion ( ALLE ) Q3 revenue grows 10.7% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, rising 6.5% yr/yr

* Company raises full-year revenue and EPS outlook, citing strong Americas performance

Outlook

* Allegion ( ALLE ) raises 2025 full-year revenue growth outlook to 7.0%-8.0%

* Company maintains 2025 organic growth outlook at 3.5%-4.5%

* Allegion ( ALLE ) raises 2025 full-year EPS outlook to $7.45-$7.55

Result Drivers

* AMERICAS NON-RESIDENTIAL - Strong performance in the Americas non-residential segment driven by price realization and volume growth

* ACQUISITIONS AND CURRENCY - Revenue growth supported by acquisitions and a positive foreign currency impact

* INTERNATIONAL SEGMENT - International segment revenue growth driven by acquisitions and currency tailwinds

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.07 $1.04

Revenue bln bln (9

Analysts

)

Q3 Beat $2.30 $2.21

Adjusted (10

EPS Analysts

)

Q3 EPS $2.18

Q3 Beat $198.70 $191.42

Adjusted mln mln (7

Net Analysts

Income )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the communications & networking peer group is "buy"

* Wall Street's median 12-month price target for Allegion PLC ( ALLE ) is $185.00, about 3% above its October 21 closing price of $179.47

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: JPMorgan Tests New Credit Card Internally as Part of UK Expansion Plans
Market Chatter: JPMorgan Tests New Credit Card Internally as Part of UK Expansion Plans
Oct 3, 2024
12:11 PM EDT, 09/20/2024 (MT Newswires) -- JPMorgan Chase ( JPM ) has started testing a new credit card internally as it looks to expand its products in the UK, Bloomberg News reported Friday, citing people familiar with the matter. This product has been under development for over a year and senior executives at JPMorgan ( JPM ) have been...
FedEx's Fiscal Q1 Miss Spurred by Slack Demand as Cost Savings Trail, Oppenheimer Says
FedEx's Fiscal Q1 Miss Spurred by Slack Demand as Cost Savings Trail, Oppenheimer Says
Oct 3, 2024
11:31 AM EDT, 09/20/2024 (MT Newswires) -- FedEx's ( FDX ) disappointing fiscal Q1 earnings reflected both slack demand and underperformance on cost savings, Oppenheimer said Friday in a report. The $390 million from the company's DRIVE initiative to reduce expenses trailed the implied run-rate of the fiscal 2025 guidance of $2.2 billion, Oppenheimer said. Revenue eased in the quarter...
Shuttle Pharmaceuticals Launches Equity Offering
Shuttle Pharmaceuticals Launches Equity Offering
Oct 3, 2024
11:36 AM EDT, 09/20/2024 (MT Newswires) -- Shuttle Pharmaceuticals Holdings ( SHPH ) said in a filing with the US Securities and Exchange Commission that it is offering common shares, pre-funded warrants to buy shares, and warrants to purchase shares. The company did not disclose the terms of the offering including pricing and number of shares, pre-funded warrants and warrants....
Brookfield reaffirms its interest in Grifols, ask more time for analysis, sources say
Brookfield reaffirms its interest in Grifols, ask more time for analysis, sources say
Oct 3, 2024
LONDON, Sept 30 (Reuters) - Canadian fund Brookfield reaffirmed its interest in a potential takeover of Spanish drugmaker Grifols and requested more time to complete due diligence for its possible bid, two sources with knowledge of the matter said on Monday. Brookfield sent a letter on Monday to the board asking for a few more weeks to complete the process...
Copyright 2023-2026 - www.financetom.com All Rights Reserved